Prothena to Report First Quarter 2021 Financial Results on May 11th
May 04 2021 - 4:05PM
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
company with expertise in protein dysregulation and a pipeline of
investigational therapeutics for rare peripheral amyloid and
neurodegenerative diseases, announced today that it will report its
first quarter 2021 financial results on Tuesday, May 11, 2021 after
the close of the U.S. financial markets.
Consistent with past practice, the Company will
not be conducting a conference call in conjunction with this
financial results release on May 11.
About Prothena
Prothena Corporation plc is a late-stage
clinical company with expertise in protein dysregulation and a
pipeline of novel investigational therapeutics with the potential
to change the course of devastating rare peripheral amyloid and
neurodegenerative diseases. Fueled by its deep scientific expertise
built over decades of research, Prothena is advancing a pipeline of
therapeutic candidates for a number of indications and novel
targets for which its ability to integrate scientific insights
around neurological dysfunction and the biology of misfolded
proteins can be leveraged. Prothena’s pipeline includes both
wholly-owned and partnered programs being developed for the
potential treatment of diseases including AL amyloidosis, ATTR
amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number
of other neurodegenerative diseases. For more information, please
visit the Company’s website at www.prothena.com and follow the
Company on Twitter @ProthenaCorp.
Contacts:
Media & InvestorsJennifer
Zibuda, Director, Investor Relations &
Communications650-837-8535, jennifer.zibuda@prothena.com
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Sep 2023 to Sep 2024